Global Hepatoblastoma Market - 2023-2030

Global Hepatoblastoma Market - 2023-2030

Global Hepatoblastoma Market reached US$ 366.7 million in 2022 and is expected to reach US$ 688.2 million by 2030 growing with a CAGR of 8.4% during the forecast period 2023-2030. The trend such as shift towards personalized medicine by better understanding of specific genetic makeup is expected to dominate the global hepatoblastoma market.

The global hepatoblastoma market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such as usage of targeted therapies, and emerging immunotherapy options.

Furthermore, rising prevalence of hepatoblastoma, advancements in diagnostic techniques and treatments, technological advancements in diagnosis, and growing awareness about the disease is driving up the hepatoblastoma market size. Due to the rising number of clinical trials has resulted in development of novel treatment is seeing an increase in demand from North American regions. With significant competitors like Eureka Therapeutics, Fennec Pharmaceuticals Inc., and others actively operating in the market.

Market Dynamics

The Growing Prevalence of Hepatoblastoma to Drive the Growth of the Hepatoblastoma Market

The rising number of cases of hepatoblastoma is a key driver driving the hepatoblastoma market's expansion. Hepatoblastoma is higly prevalent in pediatric population aging around 1 to 3 years. The factors such as gentic problems are mainly associated with these cancer, as children with Beckwith-Wiedemann syndrome or Aicardi syndrome have higher risk of developing hepatoblastoma.

For instance, according to the American Childhood Cancer Organization article, approximately 50-70 cases occurs per year in U.S. Furthermore, 95% chlidren diagnosed are under 4 years of age. Also, hepatoblastoma holds 1% of overall pediatric cancer. Moreover, better diagnostic technique have led to increase detection of these cancer. Thus, owing to the growing prevalence of these condition to drive the market over the forecast period.

The Increasing Number of Clinical Trials will Drive the Market Growth

The increasing number of clinical trials for hepatoblastoma therapy and diagnosis is a major factor contributing to this market. Clinical trials play an important role in the discovery of new therapy and diagnostic alternatives, resulting in better patient outcomes. Furthermore, the data provided by this clinical trial serves as a crucial doorway for furthering research and expanding international collaboration.

For instance, Eureka Therapeutics Inc. has been conducting a clinical trial for pediatric patients with relapsed/refractory hepatoblastoma, hepatocellular carcinoma (HCC), or hepatic neoplasms, this is a Phase I/II clinical trial to assess the safety and understand the recommended Phase II Dose (RP2D) of ET140203 T-cells. It is a interventional trial and total 15 participant have enrolled for this trial, and the estimated trial completion period is on January 2028. Thus, owing to the increasing number of clinical trials the market is expected to drive over the foreseeable future.

The Lack of Effective Therapies for Hepatoblastoma Treatment will Hamper the Growth of the Market

The lack of effective hepatoblastoma therapeutics is a significant commercial constraint. Patients have difficulties due to a lack of targeted medicines and personalized therapy alternatives. Currently, the only FDA-approved medicine for this cancer is ET140203 by Eureka Therapeutics, leaving few viable alternatives with no particular activity against the disease. Furthermore, existing treatments, such as the widely used chemotherapeutic medication Cisplatin, have unwanted side effects.

For instance, according to a 2023 article published in the Journal of the American Society of Clinical Oncology, cisplatin-induced ototoxicity has been determined to be an important barrier in cancer treatment pediatric patients. While the US FDA has approved sodium thiosulfate injection (STS) to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, nonmetastatic solid tumors based on two trials. Thus, the overall lack of effcetive medication remains a significant constraint to the market's growth.

Segment Analysis

The global hepatoblastoma market is segmented based on drug class, treatment, distribution channel, and region.

Owing to its Better Effectiveness, the Surgery Segment Accounted for Approximately 34.6% of the Hepatoblastoma Market Share

The surgery segment is poised to dominate the hepatoblastoma market as it remains a common and preferred medical treatment for hepatoblastoma owing to its effectiveness and better cure for hepatoblastoma. Surgery is the main treatment for this cancer and remain a cornerstone of management and complete resection of tumor for better cure. Furthermore, advancement in imaging technologies and adoption of minimal invasive procedure is driving the market growth

For instance, liver resection (hepatectomy) is generally a difficult surgery but using advanced techniques of imaging using 3D image-processing software and virtual simulation, this technologies helps in 3D reconstruction of liver and provide relationship between portal vein and hepatic vein.

Additionally, one of the key advances is the use of Fluorescence-induced indocyanine green (ICG) navigation surgery for determining the localization of hepatic tumors. This ICG navigation system aids in the identification and detection of tumors, thereby helping in determining the requirement for total resection during surgery. As a result, as imaging technologies advances in the future, the segment is anticipated to grow over the foreseeable period.

Geographical Penetration

North America Accounted for Approximately 39.4% of the Market Share in 2022, Owing to the Surge in Investment by the Companies

North America, particularly the United States, dominates the global hepatoblastoma market due to its presence of established market player, along with increasing funding by the companies for the development of novel treatment approaches. Furthermore, the increasing prevalence of hepatoblastoma and intensive awareness campaigns and regular screenings contribute to improved early identification and treatment outcomes.

For instance, in August 2022, Fennec Pharmaceutical Inc. based in U.S. has secured a significant investment of 45 Billion U.S. dollars from Petrichor Healthcare Capital to support their launch of PEDMARKTM medication. Moreover, additional $20 Billion will be funded upon potential FDA approval of PEDMARKTM by September 30, 2022.

Moreover, PEDMARKTM is intended to reduce ototoxicity induced by platinum-based therapies in pediatric cancer patients, addressing a vital need for nearly 10,000 children who receive such treatments each year. The FDA accepted the resubmitted New Drug Application, and PEDMARKTM was designated as Breakthrough Therapy and Fast Track. Therefore, owing to the above factors the market is expected to grow at faster rate in this region over the forecast period.

Competitive Landscape

The major global players in the hepatoblastoma market include Eureka Therapeutics, Fennec Pharmaceuticals Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Cipla Limited, Pfizer Inc., AstraZeneca, Boston Scientific Corporation, Nantong Haier's Pharmaceutical co. ltd, GSK plc. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has significat effect on the hepatoblastoma market. For instance, according to National Librabry of Medicine 2020 article, Covid19 has hampered the diagnosis and management of children with hepatoblastoma (HB), demanding multidisciplinary assessments and personalized treatment approaches. Children with both HB and COVID-19 may require anti-SARS-CoV-2 medication, and in those with concurrent infections, emergency surgery may be required for life-threatening surgical crises. Treatment recommendations for HB patients should take into account the pandemic's impact as well as regional economic factors.

For resectable tumors following fresh adjuvant chemotherapy, a ""wait and see"" strategy is suggested, while liver transplantation is considered for non-resectable tumors. COVID-19-induced abnormal chest imaging complicates cases of pulmonary metastases. The therapeutic regimen may differ depending on the nature of the emergency. Hospitals try to develop management plans based on consensus, research, and experience, responding to this changing scenario in order to give the best care for children with HB.

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is having a low impact on the global hepatoblastoma market. The conflict has surely decreased access to healthcare services in Ukraine, making it harder for hepatoblastoma patients to receive critical treatment. The increased financial load on patients as a result of treatment costs and economic instability has further hampered access to care. Delayed diagnosis and treatment have also been noted as people are unwilling to seek medical help in the midst of the conflict.

These obstacles have had a detrimental impact on the worldwide hepatoblastoma market, producing slower growth than expected. However, there is potential for development, such as a greater emphasis on creating more effective treatment options and improving hepatoblastoma awareness in Ukraine. As the war ends and healthcare access improves, the market is projected to rebound.

By Drug Class
• Alkylating Agent
• Antibiotics
• Vinca Alkaloids
• Antimetabolites
• Others

By Treatment
• Surgery
• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Ablation Therapy
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On January 31, 2023, the FDA approved sodium thiosulfate (Pedmark) for lowering the risk of cisplatin-induced ototoxicity in pediatric patients aged 1 month and older with localized, nonmetastatic solid tumors. In the SIOPEL 6 study, 39% of patients with standard-risk hepatoblastoma who got sodium thiosulfate together with cisplatin had hearing loss, compared to 68% of those who received cisplatin alone.
• On October 17, 2022, Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, announced that the FDA has granted Orphan Drug Designation (ODD) to ET140203 for the treatment of hepatoblastoma (HB), a rare childhood liver tumor that typically affects children under the age of five.

Why Purchase the Report?
• To visualize the global hepatoblastoma market segmentation based on drug class, treatment, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hepatoblastoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available as excel consisting of key products of all the major players.

The global hepatoblastoma market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies